BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26669787)

  • 1. Molecular Characteristics of Large Parathyroid Adenomas.
    Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
    World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.
    Truran PP; Johnson SJ; Bliss RD; Lennard TW; Aspinall SR
    World J Surg; 2014 Nov; 38(11):2845-54. PubMed ID: 25002250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.
    Juhlin CC; Nilsson IL; Johansson K; Haglund F; Villablanca A; Höög A; Larsson C
    Endocr Pathol; 2010 Sep; 21(3):166-77. PubMed ID: 20473645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.
    Hosny Mohammed K; Siddiqui MT; Willis BC; Zaharieva Tsvetkova D; Mohamed A; Patel S; Sharma J; Weber C; Cohen C
    Appl Immunohistochem Mol Morphol; 2017; 25(10):731-735. PubMed ID: 27490759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms.
    Kumari N; Chaudhary N; Pradhan R; Agarwal A; Krishnani N
    Endocr Pathol; 2016 Jun; 27(2):87-96. PubMed ID: 26984237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
    Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
    J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.
    Juhlin CC; Nilsson IL; Lagerstedt-Robinson K; Stenman A; Bränström R; Tham E; Höög A
    Mod Pathol; 2019 Jul; 32(8):1082-1094. PubMed ID: 30923346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining a molecular phenotype for benign and malignant parathyroid tumors.
    Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
    Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
    Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
    Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of parathyroid tumors from two patients with hereditary colorectal cancer syndromes.
    Andreasson A; Sulaiman L; do Vale S; Martins JM; Ferreira F; Miltenberger-Miltenyi G; Batista L; Haglund F; Björck E; Nilsson IL; Höög A; Larsson C; Juhlin CC
    Fam Cancer; 2012 Sep; 11(3):355-62. PubMed ID: 22395475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.
    Wang O; Wang CY; Shi J; Nie M; Xia WB; Li M; Jiang Y; Guan H; Meng XW; Xing XP
    Chin Med J (Engl); 2012 Aug; 125(16):2895-901. PubMed ID: 22932087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
    Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
    Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
    Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
    Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas.
    Kruijff S; Sidhu SB; Sywak MS; Gill AJ; Delbridge LW
    Ann Surg Oncol; 2014 Feb; 21(2):426-33. PubMed ID: 24081804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2, p53 and MIB-1 expression in normal and neoplastic parathyroid tissues.
    Naccarato AG; Marcocci C; Miccoli P; Bonadio AG; Cianferotti L; Vignali E; Cipollini G; Viacava P
    J Endocrinol Invest; 1998 Mar; 21(3):136-41. PubMed ID: 9591207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic characterization of large parathyroid adenomas.
    Sulaiman L; Nilsson IL; Juhlin CC; Haglund F; Höög A; Larsson C; Hashemi J
    Endocr Relat Cancer; 2012 Jun; 19(3):389-407. PubMed ID: 22454399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.
    Juhlin CC; Villablanca A; Sandelin K; Haglund F; Nordenström J; Forsberg L; Bränström R; Obara T; Arnold A; Larsson C; Höög A
    Endocr Relat Cancer; 2007 Jun; 14(2):501-12. PubMed ID: 17639063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
    Guarnieri V; Battista C; Muscarella LA; Bisceglia M; de Martino D; Baorda F; Maiello E; D'Agruma L; Chiodini I; Clemente C; Minisola S; Romagnoli E; Corbetta S; Viti R; Eller-Vainicher C; Spada A; Iacobellis M; Malavolta N; Carella M; Canaff L; Hendy GN; Cole DE; Scillitani A
    Cell Oncol (Dordr); 2012 Dec; 35(6):411-22. PubMed ID: 22987117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
    Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
    Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.
    Woodard GE; Lin L; Zhang JH; Agarwal SK; Marx SJ; Simonds WF
    Oncogene; 2005 Feb; 24(7):1272-6. PubMed ID: 15580289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.